The effect of Hydroxychloroquine on alloreactivity and its potential use for graft-versus-host disease

Hydroxychloroquine COVID Graft-Versus-Host Disease Q Plus News

“Hydroxychloroquine (HCQ) interferes with antigen processing and with receptor loading and recycling by raising the pH of lysosomes and endosomes.”

“HCQ thus inhibits MHC class II-restricted antigen presentation by blocking the binding of peptides to MHC molecules. Additionally, HCQ has been shown to diminish the release of several cytokines.”

“HCQ’s ability to reduce the cytotoxicity, proliferation, and TNF alpha production resulting from allorecognition suggests that it may be useful in the prevention and treatment of graft-versus-host disease (GVHD).”

pubmed.ncbi.nlm.nih.gov/8807116

 

Use of Hydroxychloroquine for the manufacture of a medicament for the treatment of graft-versus-host disease after bone marrow transplant

Hydroxychloroquine COVID Graft-Versus-Host Disease Q Plus News

“Use of hydroxychloroquine for the manufacture of a medicament for suppressing alloreactivity arising from reaction of donor T lymphocytes against recipient cells.”

Hydroxychloroquine COVID Graft-Versus-Host Disease Q Plus News“More particularly, the present invention relates to the use of hydroxychloroquine for prevention and treatment of graft-versus-host disease.”

patents.google.com/patent/EP0650…

 

Archives

  • September 2021 (3)
  • October 2020 (2)
  • September 2020 (15)
  • August 2020 (35)
  • July 2020 (31)